Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study
暂无分享,去创建一个
U. Zettl | D. Ellenberger | A. Stahmann | J. Haas | F. Fneish | Niklas Frahm | Friedemann Paul | D. Pöhlau | H. Temmes | M. Peters | Anna-Lena Röper | Sarah Schilling | Micha Löbermann
[1] U. Zettl,et al. Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic , 2022, Scientific Reports.
[2] U. Zettl,et al. SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study , 2022, The Lancet Regional Health - Europe.
[3] O. Mirmosayyeb,et al. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review , 2022, Journal of Clinical Neuroscience.
[4] U. Reimer,et al. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[5] R. Alroughani,et al. COVID-19 vaccination in people with multiple sclerosis, real-life experience , 2022, Clinical Neurology and Neurosurgery.
[6] P. Caron. Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management , 2022, Endocrine.
[7] H. Hartung,et al. Vaccination and immunotherapies in neuroimmunological diseases , 2022, Nature Reviews Neurology.
[8] R. Dalan,et al. SARS-CoV-2 mRNA Vaccination and Graves’ Disease: a report of 12 cases and review of the literature , 2022, The Journal of clinical endocrinology and metabolism.
[9] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.
[10] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.
[11] G. Marfia,et al. COVID-19 Severity in Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[12] U. Zettl,et al. Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study , 2021, European Neurology.
[13] F. Lund-Johansen,et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] A. Achiron,et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study , 2021, Journal of Neuroimmunology.
[15] G. Comi,et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis , 2021, Neurology.
[16] R. Bruno,et al. COVID vaccination and asthma exacerbation: might there be a link? , 2021, International Journal of Infectious Diseases.
[17] A. Bar-Or,et al. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[18] I. Lotan,et al. Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases , 2021, Multiple Sclerosis and Related Disorders.
[19] J. Sloane,et al. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[20] I. Lotan,et al. Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel , 2021, European journal of neurology.
[21] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.
[22] J. Abkowitz,et al. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination , 2021, Blood Advances.
[23] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[24] T. Friede,et al. Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry , 2021, Scientific Reports.
[25] V. Meca-Lallana,et al. SARS-CoV-2 Infection in Multiple Sclerosis , 2021, Neurology® Neuroimmunology & Neuroinflammation.
[26] E. Havrdová,et al. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement , 2021, Journal of Neuroimmunology.
[27] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[28] A. Achiron,et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple Sclerosis.
[29] K. Schnatbaum,et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.
[30] A. Chan,et al. Vaccine Hesitancy in Patients With Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[31] I. Pulido-Valdeolivas,et al. Incidence and Impact of COVID-19 in MS , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[32] M. Sormani,et al. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.
[33] H. Schuitemaker,et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine , 2021, The New England journal of medicine.
[34] M. Magyari,et al. Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study. , 2021, Multiple sclerosis and related disorders.
[35] A. Achiron,et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies , 2021, Therapeutic advances in neurological disorders.
[36] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[37] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[38] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[39] N. Mizuki,et al. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates , 2020, Vaccine.
[40] J. Santoro,et al. Wilhelm Uhthoff and Uhthoff’s phenomenon , 2020, Multiple sclerosis.
[41] Lu Zhang,et al. mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection , 2020, International journal of molecular sciences.
[42] H. Hartung,et al. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 , 2020, EBioMedicine.
[43] A. Strasser,et al. Paradise revealed III: why so many ways to die? Apoptosis, necroptosis, pyroptosis, and beyond , 2020, Cell Death and Differentiation.
[44] A. Winkelmann,et al. Vaccination in Multiple Sclerosis: Friend or Foe? , 2019, Front. Immunol..
[45] M. Karin,et al. NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.
[46] D. Weissman,et al. mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.
[47] Y. Ben-Shlomo,et al. Seasonal variation in multiple sclerosis relapse , 2017, Journal of Neurology.
[48] A. Langer-Gould,et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. , 2014, JAMA neurology.
[49] E. Beghi,et al. Risk of Guillain-Barré syndrome after 2010–2011 influenza vaccination , 2013, European Journal of Epidemiology.
[50] C P Farrington,et al. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice , 2011, Epidemiology and Infection.
[51] B. Hansen,et al. Optimal Full Matching and Related Designs via Network Flows , 2006 .
[52] Patrick Musonda,et al. Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.